期刊文献+

HIV-1 p15(Gag)基因的克隆、蛋白表达及抗体制备 被引量:1

Cloning,expression,and antibody preparation of HIV-1 p15(Gag)
下载PDF
导出
摘要 目的为了研究HIV-1p15(Gag)的生物学活性,制备HIV-1p15(Gag)蛋白及其特异性抗体。方法用PCR的方法扩增编码p15(Gag)基因序列,将其克隆到原核表达载体pET28a(+)中表达HIV-1p15蛋白,分别用His抗体和HIV阳性血清做western blot鉴定目的蛋白。以纯化目的蛋白为抗原免疫日本大耳白兔,制备多克隆抗体。通过酶联免疫吸附实验(ELISA),免疫细胞化学法检测抗体滴度及其特异性。结果原核表达载体pET28a(+)-p15(Gag)成功构建,可在大肠杆菌BL21(DE3)中诱导表达,得到相对分子质量约20000的p15(Gag)蛋白经western blot鉴定正确。纯化蛋白免疫家兔,制备的多克隆抗体具有较强免疫特异性。结论得到纯化的HIV-1p15蛋白,制备的多克隆抗体能够检测自然状态下病毒蛋白p15(Gag),为进一步研究HIV-1奠定了实验基础。 Objective To prepare HIV-1 p15(Gag) protein and its antibody for studying the biological activity of HIV-1p15(Gag). Methods The full length gene fragment of p15(Gag) was amplified by PCR, and then cloned into pET28a( + ) prokaryotic expressing vector. pET28a( + )-p15(Gag) was induced by IPTG in E. coli BL21 and the expressed protein was detected by Western blot assay. The purified protein was used to immune rabbits for preparing polyclonal antibody. The specificity and titer of the antibody were identified with ELISA and immunohistochemistry, respectively. Results The plasmid pET28-p15(Gag) was successfully constructed and HIV-1 p15(Gag) protein could be expressed in E. coli BL21 with high efficiency. The recombinant protein was characterized with anti-his and HIV-1 positive plasma by Western blot assay. Rabbit immunized with the purified protein produced high titer antibody. The viral protein expressed in eukaryotic cells was specifically combined with the antibody detected by immunohistochenaistry. Conclusion Purified protein HIV-1 p15 with high antigenicity is obtained. Prepared polyclonal antibody can be used to detect the viral protein that expressed in eukaryotic cells, which provides rehable tools for the future HIV-1 research.
出处 《免疫学杂志》 CAS CSCD 北大核心 2008年第3期352-355,共4页 Immunological Journal
基金 湖北省卫生厅课题(JX3C06) 三峡大学人才基金资助项目
关键词 HIV-1 p15(Gag)基因 原核表达 免疫原性 多克隆抗体 HIV-1 gag gene p15 Prokaryotic expression Antigenicity Polyclonal antibody
  • 相关文献

参考文献7

二级参考文献36

  • 1尹春煜,卢洪洲,蒋卫民,胡越凯,赵清霞,何云,潘孝彰,翁心华.HIV-1gag基因p24编码区的变异性分析[J].复旦学报(医学版),2004,31(4):371-374. 被引量:1
  • 2林剑萍,王华,王玲,卫红飞,胡晓平,王丽颖,于永利.HIV-1Tat基因的融合构建及在大肠杆菌中的高效表达[J].细胞与分子免疫学杂志,2005,21(1):33-36. 被引量:6
  • 3UNAIDS.AIDS epidemic update[R]. Geneva: UNAIDS, 2002:3.
  • 4Smith AJ, Srinivasakumar N, Hammarskjold ML, et al. Requirements for incorporation of Pr 160gag-pol from human immunodeficiency Virus type 1 into virus-like particles [J]. J Virol, 1993, 67(4): 2 266-2 275.
  • 5Alexandra B, Ludwig D, Ralf W, et al. The past, present and future of HIV-vaccine development: a critical view [J]. DTT, 2002, 7 (1): 36-46.
  • 6Hu SL, Polacino P, Stallard V, et al. Recombinant subunit vaccines as an approach to study correlates of protection against primate lentivirus infection [J]. Immunol Lett, 1996,51(1/2): 115-119.
  • 7Bennet B, Check IJ, Olsen MR, et al. A comparison of commercially available adjuvants for use in reseach[J]. J Immunol Methods, 1992,153(1/2): 31-40.
  • 8Cooper PD, McComb C, Steele EJ, et al. The adjuvanticity of Algammulin, a new vaccine adjuvant [J]. Vaccine, 1991, 9(6): 408-415.
  • 9Luke W, Coulibaly C, Dittmer U, et al. Simian immunodeficiency virus (SIV) gp130 oligomers protect rhesus macaques against the infection with SIVmac32H grown on T-cells or derived ex vivo [J]. Virol, 1996, 216(2): 444-450.
  • 10Hu SL, Abrams K, Barber GN, et al. Protection of macaques of against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160[J].Science,1992, 255(5 043):456-459.

共引文献4

同被引文献6

  • 1王路,白雪,刘红亮,张高红,郑永唐.重组腺病毒载体vAd-tat的构建及其在细胞中的表达[J].免疫学杂志,2009(2):168-172. 被引量:7
  • 2Wainberg MA, Martinez Cajas JL. Sequencing of therapy to avoid resistance and the need for new antiretroviral drugs in the treatment of HIV disease [J]. Infect Disord Drug Targets, 2009, 9 (2): 172-190.
  • 3Ventoso I, Navarro J, Munoz MA, et al. Involvement of HIV-1 protease in virus-induced cell killing [J]. Antiviral Res, 2005, 66 (1):47-55.
  • 4Chaix ML, Descamps D, Wirden M, et al. Stable frequency of HIV-1 transmitted drug resistance in palients at the time of primary infection over 1996-2006 in France [J]. AIDS, 2009, 23 (6): 717-724.
  • 5Gehringer H, Von der Helm K, Seelmeir S, et al. Development and evaluation of a phenotypic assay monitoring resistance formation to protease inhibitors in HIV-1-infected patients[J]. J Virol Methods, 2003, 109 (2): 143-152.
  • 6Bartonova V, Kral V, Sieglova I, et al. Potent inhibition of drug-resistant HIV protease variants by monoclonal anti- bodies[J]. Antiviral Res, 2008, 78 (3): 275-277.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部